Evotec SE (ETR:EVT – Get Rating)’s share price was down 1% during mid-day trading on Tuesday . The stock traded as low as €22.57 ($23.76) and last traded at €22.92 ($24.13). Approximately 286,952 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 1,360,000 shares. The stock had previously closed at €23.14 ($24.36).
EVT has been the subject of a number of recent analyst reports. Royal Bank of Canada set a €43.00 ($45.26) price objective on shares of Evotec in a research note on Tuesday, May 17th. Warburg Research set a €43.00 ($45.26) price objective on shares of Evotec in a research note on Wednesday, May 11th. Deutsche Bank Rese… set a €30.00 ($31.58) price objective on shares of Evotec in a research note on Tuesday, May 31st. Morgan Stanley set a €42.00 ($44.21) price objective on shares of Evotec in a research note on Friday, April 29th. Finally, Jefferies Financial Group set a €45.00 ($47.37) target price on shares of Evotec in a research note on Wednesday, May 11th.
The company has a debt-to-equity ratio of 39.59, a quick ratio of 2.91 and a current ratio of 3.13. The business’s 50 day simple moving average is €24.31 and its 200-day simple moving average is €29.81. The company has a market cap of $4.17 billion and a price-to-earnings ratio of 44.68.
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.